Harvard-born diabetes startup Semma reports advances in turning stem cells into insulin producers

Harvard-born diabetes startup Semma reports advances in turning stem cells into insulin producers

Source: 
Fierce Biotech
snippet: 

Semma Therapeutics has faced an obstacle with its process of turning undifferentiated pluripotent stem cells into insulin-producing pancreatic beta cells: Only 30% of the resulting cells turn out to be beta cells. Now, a Semma-Harvard University team has figured out how to boost the proportion of beta cells emerging from their process to 80%.